Wernicke, Joachim

Core outcome measures for chronic pain clinical trials: IMMPACT recommendations

Dworkin, R. H., Turk, D. C., Farrar, J. T., Haythornthwaite, J. A., Jensen, M. P., Katz, N. P., Kerns, R. D., Stucki, G., Allen, R. R., Bellamy, N., et al. (2005) · Pain

Musculoskeletal pain and rehabilitationDelphi Technique in Research

Cited by 3,732

Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies

Michelson, D., Adler, L., Spencer, T., Reimherr, F. W., West, S. A., Allen, A. J., Kelsey, D., Wernicke, J., Dietrich, A., & Milton, D. (2003) · Biological Psychiatry

Attention Deficit Hyperactivity DisorderNeurotransmitter Receptor Influence on Behavior

Cited by 790

Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Randomized, Placebo-Controlled, Dose-Response Study

Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F. R., Spencer, T., & the Atomoxetine ADHD Study Group (2001) · Pediatrics

Attention Deficit Hyperactivity DisorderPharmaceutical studies and practices

Cited by 666

Once-Daily Atomoxetine Treatment for Children and Adolescents With Attention Deficit Hyperactivity Disorder: A Randomized, Placebo-Controlled Study

Michelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., Newcorn, J., Sallee, F. R., Sangal, R. B., Saylor, K., et al. (2002) · American Journal of Psychiatry

Attention Deficit Hyperactivity DisorderPharmaceutical studies and practices

Cited by 599

A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder

Arnold, L. M., Rosen, A., Pritchett, Y. L., D'Souza, D. N., Goldstein, D. J., Iyengar, S., & Wernicke, J. F. (2005) · Pain

Fibromyalgia and Chronic Fatigue Syndrome ResearchPain Mechanisms and Treatments

Cited by 471

Cardiovascular Effects of Atomoxetine in Children, Adolescents, and Adults

Wernicke, J. F., Faries, D., Girod, D., Brown, J. W., Gao, H., Kelsey, D., Quintana, H., Lipetz, R., Michelson, D., & Heiligenstein, J. (2003) · Drug Safety

Attention Deficit Hyperactivity DisorderBlood Pressure and Hypertension Studies

Cited by 191

Hepatic Events Associated with Atomoxetine Treatment for??Attention-Deficit??Hyperactivity Disorder

Bangs, M. E., Jin, L., Zhang, S., Desaiah, D., Allen, A. J., Read, H. A., Regev, A., & Wernicke, J. F. (2008) · Drug Safety

Drug-Induced Hepatotoxicity and ProtectionPharmacovigilance and Adverse Drug Reactions

Cited by 68

QT Correction Methods in Children and Adolescents

WERNICKE, J. F., FARIES, D., BREITUNG, R., & GIROD, D. (2005) · Journal of Cardiovascular Electrophysiology

Cardiac electrophysiology and arrhythmiasPharmaceutical studies and practices

Cited by 47

Answers to the Most Common Questions About the Hepatic Safety Profile of Duloxetine

Wohlreich, M. M., Acharya, N., Strombom, I., Kuritzky, L., Robinson, M., Heinloth, A. N., Regev, A., & Wernicke, J. F. (2008) · Postgraduate Medicine

Drug-Induced Hepatotoxicity and ProtectionPharmacovigilance and Adverse Drug Reactions

Cited by 12